Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.

"CONFLICT OF INTEREST Yann‐Alexandre Vano received consultancy fees from BMS, MSD, Ipsen, Merck, Pfizer, Novartis. Gwenaelle Gravis: consultancy fees were received by her institution from BMS, Pfizer, MSD, Alliance Merck‐Pfizer; fees received by her institution for coordinating PI role from BMS. Denis Maillet received consultancy fees from BMS, Ipsen, Pfizer, MSD. Delphine Borchiellini: received consultancy fees from Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Pfizer; clinical research funding (institution) from: Astellas, AstraZeneca, Bayer, BMS, Exelixis, Infinity, Janssen, MSD, Pfizer, Roche, Taiho Oncology. Philippe Barthelemy received consultancy fees from BMS, Ipsen Pfizer, Merck MSD Novartis. Raffaele Ratta received consultancy fees from BMS, MSD, Ipsen, Merck, Pfizer. Sheik Emambux received consultancy fees from BMS and IPSEN. Stéphane Oudard received consultancy fees from Merck, Novartis, Pfizer, BMS, Ipsen. Mostefa Bennamoun, Letuan Phan, Iphigénie Korakis, Friederike Schlürmann, Nadine Houede, Delphine Topart, Thomas Ryckewaert, Ali Hasbini, Sophie Hans, Sandra Cournier, Elena Braychenko, Réza‐Thierry Elaidi: none."

"Funding information Ipsen"